We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

More, please

27 January 2004 By Robert Cyran

Sanofi’s bid values the FrancoGerman drugs maker at a 11% discount to its standalone fair value that is before counting any synergies. This leaves scope for a valuebased defence.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)